HTS |
High-throughput screening |
VDR |
Vitamin D receptor: NR1I1 |
AF-1 |
Activation function 1 |
Zn |
Zinc |
DBD |
DNA-binding domain |
NLS |
Nuclear localization signal |
LBD |
Ligand-binding domain |
AF-2 |
Activation function 2 |
ER |
Estrogen receptor, ERα: NR3A1, ERβ: NR3A2 |
AR |
Androgen receptor: NR3C4 |
RXR |
Retinoid X receptor, RXRα: NR2B1, RXRβ: NR2B2, RXRγ: NR2B3 |
PPIs |
Protein–protein interactions |
HSP |
Heat shock protein |
NMR |
Nuclear magnetic resonance |
SPR |
Surface plasmon resonance |
LOPAC |
Library of Pharmacologically Active Compounds |
PPAR |
Peroxisome proliferator activated receptor, PPARα: NR1C1, PPARβ/δ: NR1C2, and PPARγ: NR1C3 |
T2D |
Type 2 diabetes |
PSCs |
Pluripotent stem cells |
Em |
Embryonic |
ExEm |
Extraembryonic |
LNCaP |
Lymph Node Carcinoma of the prostate |
TNF |
Tumor Necrosis Factor |
NF |
Nuclear factor |
GFP |
Green fluorescence protein |
NIH |
National Institutes of Health |
FXR |
Farnesoid X receptor, FXR: NR1H4, FXRβ: NR1H5 |
FRET |
Fluorescence resonance energy transfer |
FDA |
Food and Drug Administration |
SBDD |
Structure-based drug discovery |
NCATS |
National Center for Advancing Translational Sciences |
NCGC |
NCATS Chemical Genomics Center (NCGC) |
ELF |
European Lead Factory |
SMEs |
Small and medium enterprises |
CNCL |
Chinese National Compound Library |
DDI |
Drug Discovery Initiative |
BINDS |
Basis for Supporting Innovative Drug Discovery and Life Science Research |
CAR |
Constitutive androstane receptor: NR1I3 |
GR |
Glucocorticoid receptor: NR3C1 |
LXR |
Liver X receptor, LXRα: NR1H3, LXRβ: NR1H2 |
PR |
Progesterone receptor: NR3C3 |
PXR |
Pregnane X receptor: NR1I2 |
RAR |
Retinoic acid receptor, RARα: NP1B1, RARβ: NP1B2, RARγ: NR1B3 |
TR |
Thyroid hormone receptor, TRα: NP1A1, TRβ: NP1A2 |